Enhanced MPTP neurotoxicity after treatment with isoflurophate or cholinergic agonists.
Administration of the irreversible cholinesterase inhibitor isoflurophate (diisopropylfluorophosphate, DFP) before 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) enhanced the loss in tyrosine hydroxylase activity and dopamine and 3,4-dihydroxy-phenylacetic acid content in the striatum of mice in a dose-dependent manner. The effect of DFP on the MPTP-induced changes of dopaminergic markers was evident 30 days after initiating treatment, suggesting augmented neurotoxicity. Neurotoxicity was also enhanced by prior treatment with nicotine, carbachol or oxotremorine. We conclude that activation of either muscarinic or nicotinic receptors enhances the neurotoxicity of MPTP.
Hadjiconstantinou
M
M
Department of Psychiatry, Ohio State University, College of Medicine, Columbus.
Hubble
J P
JP
Wemlinger
T A
TA
Neff
N H
NH
D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000109:Acetylcholine / Q000378:metabolism; D000818:Animals; D002217:Carbachol / Q000494:pharmacology; D003342:Corpus Striatum / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D004357:Drug Synergism; D007531:Isoflurophate / Q000494:pharmacology*; D020267:MPTP Poisoning; D008297:Male; D051379:Mice; D009538:Nicotine / Q000494:pharmacology; D010095:Oxotremorine / Q000494:pharmacology; D010277:Parasympathomimetics / Q000494:pharmacology*; D011950:Receptors, Cholinergic / Q000187:drug effects; D014446:Tyrosine 3-Monooxygenase / Q000037:antagonists & inhibitors / Q000378:metabolism
D010277:Parasympathomimetics; D011950:Receptors, Cholinergic; D015102:3,4-Dihydroxyphenylacetic Acid; D007531:Isoflurophate; D010095:Oxotremorine; D009538:Nicotine; D002217:Carbachol; D014446:Tyrosine 3-Monooxygenase; D000109:Acetylcholine; D004298:Dopamine